Clinical Trials Logo

Myasthenia Gravis Generalised clinical trials

View clinical trials related to Myasthenia Gravis Generalised.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT00408213 Completed - Clinical trials for Myasthenia Gravis Generalised

A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.

Start date: June 2004
Phase: Phase 3
Study type: Interventional

This 2 arm study will provide optional continuation of double-blind treatment with CellCept or placebo, in patients with myasthenia gravis who have achieved good symptom control in study WX17798. Patients who have completed 36 weeks of treatment in study WX17798, with stable prednisone dosing for the last 4 weeks, can continue on blinded treatment with CellCept (1g bid) or placebo until the database for WX17798 is locked and unblinded. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.